[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606192":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":22,"interventions":36,"overallOfficials":46,"centralContacts":53,"locations":59,"responsibleParty":76,"collaborators":11,"id":78,"slug":11,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":11,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment.",null,"week 12",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"DOUBLE",[20,21],"PARTICIPANT","INVESTIGATOR",[23,28,31],{"label":24,"type":25,"description":11,"interventionNames":26},"VC005 Tablets Low Dose groups","EXPERIMENTAL",[27],"Drug: VC005 tablets",{"label":29,"type":25,"description":11,"interventionNames":30},"VC005 Tablets High Dose groups",[27],{"label":32,"type":33,"description":11,"interventionNames":34},"VC005 Tablets Placebo groups","PLACEBO_COMPARATOR",[35],"Drug: VC005 Tablets Placebo",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"DRUG","VC005 tablets","VC005 groups repeat administration for 48 weeks",[29,24],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":11},"VC005 Tablets Placebo","VC005 placebo groups repeat administration for 48 weeks",[32],[47,51],{"name":48,"affiliation":49,"role":50},"Zhanguo Li","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",{"name":52,"affiliation":49,"role":50},"Xu Liu",[54],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"xiaojuan lai","CONTACT","15358160458","lai_xiaojuan@vcarepharmatech.com",[60],{"facility":49,"status":61,"city":62,"state":63,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":67,"coordinates":68},"Point",[69,70],116.39723,39.9075,{"lat":70,"lon":69},[73],{"name":48,"role":56,"phone":74,"phoneExt":11,"email":75},"13910713924","Zgli99@aliyun.com",{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606192",false,"NCT07172360","Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.","A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;\n* The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;\n* The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis\n\nExclusion Criteria:\n\n* Those who may be allergic to VC005, similar drugs or their excipients.\n* Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.\n* Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.","ALL","18 Years","70 Years",{"count":88,"type":89},420,"ESTIMATED","INTERVENTIONAL",[92],"PHASE3","This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.",[95],"Active Ankylosing Spondylitis","2025-12-29",{"date":98,"type":99},"2026-01-02","ACTUAL",{"date":101,"type":99},"2025-12-26",{"date":103,"type":89},"2027-08-30",{"name":5,"class":6},1]